SynthesisCell and tissue banking2026
Osseointegration of dental implants: a systematic review and meta-analysis of evidence from preclinical animal models and human studies.
Synthesis in Cell and tissue banking, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-term success of dental implants depends on rapid and stable osseointegration. Numerous surface treatments and biologic adjuncts have been proposed to enhance early bone anchorage, but the strength and consistency of the available preclinical and clinical evidence remain uncertain. To synthesise evidence from preclinical animal models and human clinical studies evaluating the influence of titanium implant surface modifications, biologic adjuncts, and systemic factors on osseointegration-related outcomes. A protocol was established following the PRISMA 2020 guidelines and subsequently registered with PROSPERO (CRD420251153021). A comprehensive search was conducted across PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar from their inception through December 2025. The studies included in this review comprised both in vivo animal research and human clinical trials that examined modified titanium implant surfaces, supplementary biological therapies or systemic modifiers, and provided quantitative outcomes related to osseointegration. The primary outcomes measured were bone-to-implant contact percentage (BIC%), implant stability quotient (ISQ), changes in marginal bone levels, radiographic bone density, and bone volume fraction. The risk of bias was evaluated using the SYRCLE tool, Cochrane RoB 2.0, and the JBI checklist where applicable. Animal and human evidence were synthesized qualitatively, whereas random-effects meta-analysis was performed only for clinically comparable human studies reporting common outcomes. Fourteen studies met the inclusion criteria (eight animal and six human). Roughened, hydrophilic, nanostructured, UV- or plasma-activated surfaces, as well as platelet-derived concentrates and concentrated growth factors, generally demonstrated favourable effects on osseointegration-related outcomes, including higher BIC, bone volume, and earlier implant stability, whereas diabetes and pharmacologic VEGF blockade were associated with impaired osseointegration. Pooled analysis of four human trials showed higher ISQ values for test interventions (SMD 1.37; 95% CI 1.02-1.73; P < 0.00001; I
Indexed as
Identifiers
42782540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.